

PHOTOMETABOLISM OF 7-DEHYDROCHOLESTEROL TO PREVITAMIN D<sub>3</sub> IN SKIN

M.F. Holick, J.E. Frommer, S.C. McNeill, N.M. Richtand,  
J.W. Henley, and J.T. Potts, Jr.

Department of Medicine, Harvard Medical School, and Endocrine  
Unit, Massachusetts General Hospital, Boston, Mass. 02114


Received March 21, 1977

**SUMMARY:** The photometabolism of [3 $\alpha$ -<sup>3</sup>H]-7-dehydrocholesterol in skin was studied in groups of rats exposed to ultraviolet irradiation. The major photolytic product was identified as previtamin D<sub>3</sub> by its identical migration with authentic previtamin D<sub>3</sub> on high-pressure liquid chromatography. Furthermore, this photometabolite was isolated in pure form from endogenous precursors in skins of rats exposed to ultraviolet irradiation; identification as previtamin D<sub>3</sub> was based on its ultraviolet absorption spectrum, mass spectrum and its thermal conversion to vitamin D<sub>3</sub>.

**INTRODUCTION:** Vitamin D, a fat-soluble factor that acts to heal rachitic lesions, was discovered in the early 1900's (1,2). Subsequently, Steenbock (3) and Hess et al. (4) independently demonstrated that this factor could be generated simply by irradiating either rachitic animals or their food. Further work led to the isolation and structural identification of vitamins D<sub>2</sub>, D<sub>3</sub>, and their precursors, ergosterol and 7-dehydrocholesterol, respectively (5-7).

Photolysis of ergosterol or 7-dehydrocholesterol in vitro yields, at equilibrium, at least three isomeric products: tachysterol, lumisterol, and a 9,10-seco-steroid with a 5,6-cis-triene conformation. This latter compound was shown to have antirachitic activity and, depending on the starting material, ergosterol or 7-dehydrocholesterol, was named vitamin D<sub>2</sub> or vitamin D<sub>3</sub>, respectively. At first it was believed that 7-dehydrocholesterol and ergosterol were converted directly to vitamin D<sub>3</sub> and vitamin D<sub>2</sub> by ultraviolet photolysis (8). In 1949, however, Velluz et al. (9) demonstrated that a 6,7-cis isomer, which they named previtamin D, was the initial irradiation product and that, at varying rates as a function

Abbreviations: HPLC, High-Pressure Liquid Chromatography; TLC, Thin Layer Chromatography



**Fig. 1.** Photometabolism of 7-dehydrocholesterol to lumisterol, tachysterol, and previtamin D<sub>3</sub>, which is converted to vitamin D<sub>3</sub> by thermal energy.

of temperature, previtamin D converted to vitamin D with the equilibrium position in favor of vitamin D. Thus, under controlled conditions, ultraviolet irradiation of 7-dehydrocholesterol generates three major products: tachysterol, lumisterol, and previtamin D<sub>3</sub> (Fig. 1). Previtamin D<sub>3</sub> is then converted to the thermodynamically favored 5,6-cis isomer, vitamin D<sub>3</sub>, by thermal equilibration.

Although it has been generally accepted that vitamin D<sub>3</sub> is generated in vivo by ultraviolet irradiation of the 7-dehydrocholesterol in the skin, the mechanism by which this occurs has not been investigated. We have examined this mechanism and clearly demonstrated that 7-dehydrocholesterol is initially converted to previtamin D<sub>3</sub> in the skin in vivo, as it is in the test-tube model, by the action of ultraviolet light.


## METHODS:

Synthesis of [3 $\alpha$ -<sup>3</sup>H]-7-dehydrocholesterol. Synthesis of this isotope was carried out as described for [3 $\alpha$ -<sup>3</sup>H]-ergosterol (10). Crystalline 7-dehydrocholesterol was oxidized to 4,7-cholestadiene-3-one ( $\lambda_{\max}$  240 nm) by the method of Shepherd et al. (11). This  $\alpha$ - $\beta$  unsaturated ketone was acetylated with acetic anhydride and pyridine, and the isolated product exhibited  $\lambda_{\max}$  331, 316, and 303 nm, which is characteristic for the  $\Delta^5,7$ -enol acetate. The enol acetate (10 mg) was dissolved in 10 ml isopropanol containing 100  $\mu$ l H<sub>2</sub>O and to this solution was added 1 mg [<sup>3</sup>H]-sodium borohydride (S.A. 8.0 Ci/mM) purchased from New England Nuclear, Boston, Massachusetts. The mixture was stirred at 25°C for 2 h and then extracted with ether:water. The product was dried under N<sub>2</sub> and applied to preparative thin-layer chromatographic plates (Uniplate, Analtech Inc., Delaware) and developed in n-hexane:ethylacetate (8:2 v/v). The compound with an R<sub>f</sub> of 0.6 was eluted and exhibited an ultraviolet spectrum with  $\lambda_{\max}$  295, 282, and 271 nm, which is identical to the ultraviolet spectrum for 7-dehydrocholesterol (10). Furthermore, this product migrated identically with authentic 7-dehydrocholesterol on thin-layer chromatography (TLC) and on high-pressure liquid chromatography (HPLC) using a 0.4-mm $\times$ 30-cm  $\mu$ -Porasil column developed with 1% isopropanol in n-hexane. An additional product with an identical ultraviolet-absorption spectrum but with an R<sub>f</sub> of 0.8 was also recovered; the latter did not migrate with 7-dehydrocholesterol on HPLC or TLC. This additional compound was presumed to be [3 $\beta$ -<sup>3</sup>H]-3-epi-7-dehydrocholesterol, a predicted side-product of the reduction reaction.

Topical application and irradiation of [3 $\alpha$ -<sup>3</sup>H]-7-dehydrocholesterol. Areas (3 X 3 cm) of the backs of two groups of vitamin-D-deficient rats were shaved. Two  $\mu$ Ci of [3 $\alpha$ -<sup>3</sup>H]-7-dehydrocholesterol dissolved in 0.1 ml of Wesson oil was applied to this exposed skin 24 h after shaving. The control group was kept in the dark; the treatment group, after an additional 24-h delay, was placed under an ultraviolet light of wave-length 250–350 nm for 3 h (0.23 joules/cm<sup>2</sup> at  $\lambda_{280}$  nm). Immediately after irradiation of the treatment group, all animals were killed by exsanguination, and the 3x3-cm area of skin was removed and frozen on Dry Ice.

Isolation and identification of radioactive photolysis products. Individual skins were homogenized in 10 ml 0.9% saline with a Polytron homogenizer for 30 sec and extracted with 40 ml chloroform:methanol (1:1). The chloroform phase was collected, and the aqueous phase was re-extracted twice with 10 ml chloroform. The chloroform phases were combined, dried under N<sub>2</sub> at 4°C, dissolved in n-hexane:chloroform (19:1), and applied to a 1x60-cm glass column packed with 15 grams of a Neodox-1518 alkoxyl derivative of Sephadex LH-20 prepared according to the procedure of Ellingboe et al. (12). The column was eluted with n-hexane:chloroform (19:1). Fractions (2 ml) were collected, dried under air, and dissolved in Instagel (Packard) prior to counting of their tritium content in the Packard Tricarb 3375 scintillation counter.


The various peaks of radioactivity were identified by taking individual peak fractions from the Neodox column and subjecting them to chromatography simultaneously with standard compounds on HPLC equipped with a 0.4-cm $\times$ 30-cm  $\mu$ -Porasil column using 1% isopropanol in n-hexane as solvent. The peak assigned as previtamin D<sub>3</sub> was mixed with 100  $\mu$ g authentic previtamin D<sub>3</sub>, chromatographed on HPLC as described above, and collected in 1-ml fractions. Half of each fraction was dried and counted for tritium. The remaining fractions containing the previtamin-D<sub>3</sub> peak were pooled and warmed at 60°C in methanol for 3 h before re-chromatography on the same column under identical conditions.



**Fig. 2.** Neodox 1518 Sephadex column (1 x 60 cm packed in 19:1 n-hexane:chloroform) profiles of skin lipid extracts from animals treated with topical application of 2  $\mu\text{Ci}$   $[3\alpha-^3\text{H}]\text{-7-dehydrocholesterol}$  and then killed 24 h later (A) or irradiated with 0.23 joules/cm<sup>2</sup> and then killed (B).

**Isolation and identification of a sterol formed from photolysis of endogenous 7-dehydrocholesterol.** 50 rats previously maintained on a vitamin-D-deficient diet for 3 weeks were shaven as before. 24-h later they were exposed to 0.23 joules/cm<sup>2</sup> at  $\lambda_{280\text{ nm}}$  of ultraviolet light over a period of 2 h and then immediately killed by exsanguination. Topical doses of  $[3\alpha-^3\text{H}]\text{-7-dehydrocholesterol}$  were applied to 3 rats as described above, before irradiation, to act as a radio-active marker. The shaved skin from all animals was collected, homogenized and extracted as previously described. The extract was dried under N<sub>2</sub> in the cold room and the lipid residue was re-extracted in 800 ml water:n-hexane (1:1). The n-hexane phase was collected, and the aqueous phase was re-extracted twice with 100 ml n-hexane. The n-hexane phases were combined and dried under N<sub>2</sub> at 4°C, and the residue was dissolved in n-hexane:chloroform (19:1) and applied to a 3x40-cm glass column packed with 60 g Neodox-1518 derivative of Sephadex LH-20 in the same solvent. The previtamin-D<sub>3</sub> peak was collected, dried under N<sub>2</sub>, redissolved in 10 ml methanol, and warmed at 60°C for 3 h. The product was applied to the HPLC, and 50  $\mu\text{l}$  from the resulting 1-ml fractions was counted for tritium. Ultraviolet-absorption spectra were made on the previtamin-D<sub>3</sub> peak before and after heating, on a Beckman DB-G spectrophotometer.

**RESULTS:** The chromatographic profiles of the skin extracts from animals given topical applications of  $[3\alpha-^3\text{H}]\text{-7-dehydrocholesterol}$  and then exposed to 0.23 joules/cm<sup>2</sup> ultraviolet radiation (A) or confined in the dark (B) are



**Fig. 3.** Chromatography of fractions 35—45 from Fig. 2B with 100  $\mu$ g of authentic previtamin  $D_3$  on HPLC (A). Peak I was collected and warmed at  $65^\circ\text{C}$  for 3 h and rechromatographed on the same column (B), which demonstrated conversion to vitamin  $D_3$ .

shown in Fig. 2. The chromatogram from the confined animals shows three peaks. The earliest peak (fractions no. 10—20) is presumed to be an ester(s) of the starting material. The two additional peaks were tentatively identified as 7-dehydrocholesterol and its  $\Delta^7$  reduction product, cholesterol. This identification was confirmed by cochromatography with authentic compounds on HPLC. The chromatogram from animals that received ultraviolet irradiation demonstrated one additional major peak labeled as previtamin  $D_3$  (Fig. 2B). The identification of this radioactive peak as previtamin  $D_3$  was established by (i) identical mobility with authentic previtamin  $D_3$  on the high-resolution HPLC system and (ii), after warming, identical mobility with vitamin  $D_3$  formed by thermal conversion of authentic previtamin  $D_3$  (Fig. 3).




Fig. 4. Ultraviolet absorption spectrum of the isolated product from the skin that was warmed at 65° for 3 h and chromatographed on HPLC as shown in Fig. 3.

DISCUSSION: Although it has been generally accepted that vitamin D<sub>3</sub> is made in the skin by the action of solar ultraviolet irradiation on 7-dehydrocholesterol, the mechanism by which this occurs has never been investigated. In this paper we present evidence that 7-dehydrocholesterol in the skin is converted to previtamin D<sub>3</sub> and not vitamin D<sub>3</sub>, a result similar to that seen in vitro. This was demonstrated by two methods. In the first, [3α-<sup>3</sup>H]-7-dehydrocholesterol applied topically was converted to a compound that migrated identically with authentic previtamin D<sub>3</sub> on high-resolution separation systems. The concern that topically applied 7-dehydrocholesterol might not enter epithelial cells where the photolytic reaction naturally occurs was lessened when it was demonstrated that cholesterol was generated from its precursor 7-dehydrocholesterol. Therefore, at least some of the 7-dehydrocholesterol had to enter viable epithelial cells for the 7-dehydrocholesterol-reductase to work.

It could be argued, however, that the photolytic products recovered were similar to those that would be found if we applied 7-dehydrocholesterol

to a piece of glass and irradiated it. Therefore, the previtamin  $D_3$  that we observed in our isotope experiments might in fact have been an artefact generated on the surface of the skin and may not have entered the cells or be a physiological product.

To eliminate this possibility an alternate approach was used. We irradiated 50 vitamin-D-deficient rats and isolated a product with an ultraviolet absorption spectrum  $\lambda_{\max}$  257 nm and  $\lambda_{\min}$  230 nm that was similar to previtamin  $D_3$  ( $\lambda_{\max}$  260 nm,  $\lambda_{\min}$  230 nm). This product, formed from endogenous 7-dehydrocholesterol, migrated identically with authentic previtamin  $D_3$  and, when warmed at 60°, chromatographed identically with vitamin  $D_3$ . Furthermore, the product after heating had an ultraviolet absorption spectrum  $\lambda_{\max}$  265 nm,  $\lambda_{\min}$  228 nm, which is identical to that of the 5,6-cis-triene system for vitamin  $D_3$  (Fig. 4). To confirm that the isolated 5,6-cis-triene was vitamin  $D_3$ , a mass spectrum of the isolated product was analyzed. The compound was shown to have a molecular ion 384 (m/e) and fragments 369 ( $M^+ - CH_3$ ), 366 ( $M^+ - H_2O$ ), 271 ( $M^+ - \text{side chain}$ ), 253 ( $M^+ - \text{side chain} - H_2O$ ), 136 (A ring +  $C_6$  and  $C_7$ ), and 118 ( $136 - H_2O$ ), which are identical to authentic vitamin  $D_3$  (13).

In this paper we report the isolation of a photolytic product from skin and its identification as previtamin  $D_3$ . Therefore we suggest that the mechanism for the photoconversion of 7-dehydrocholesterol to vitamin  $D_3$  in the skin occurs through an intermediate product, previtamin  $D_3$ , which is further converted to vitamin  $D_3$  presumably by the thermal action of body heat. Qualitative or quantitative differences, if any, in the overall process of photolytic activation of 7-dehydrocholesterol in vitro versus in vivo await further study, especially the issue of biological control of the in vivo process.

ACKNOWLEDGEMENTS: We wish to thank Dr. M.B. Clark, Dr. S.A. Holick, and L.B. Fred for editorial assistance. This work was supported by N.I.H. Grant AM 17459 and AM 11794 and the John A. Hartford Foundation. J.W.H. is the recipient of a New Zealand M.R.C. Overseas Fellowship.

## REFERENCES

1. Mellanby, E. (1919) *Lancet*, 1, 407—412.
2. McCallum, E.V., Simmonds, N., Becker, J.E., and Shipley, P.G. (1922) *Bull. John Hopkins Hosp.*, 33, 229—232.
3. Steenbock, H. (1924) *Science*, 60, 224—227.
4. Hess, A.F., Weinstock, M., and Helman, F.D. (1925) *J. Biol. Chem.*, 63, 305—308.
5. Askew, F.A., Bourdillon, R.B., Bruce, H.M., Jenkins, R.G.C., and Webster, T.A. (1931) *Proc. Roy. Soc. Med.*, B107, 76—78.
6. Windaus, A., Lettre, H., and Schenck, F. (1935) *Justus Leibigs Ann. Chem.*, 520, 98.
7. Windaus, A., Schenck, F., and von Werder, F. (1936) *Hoppe-Seyler's Physiol. Chem.*, 241, 100—104.
8. Rosenheim, O., and King, H. (1935) *Chem. Ind. (London)*, 54, 699—671.
9. Velluz, L., Amiard, G., and Petit, A. (1949) *Bull. Soc.*, 16, 501—503.
10. Jones, G., Schnoes, H.K., and DeLuca, H.F. (1975) *Biochemistry*, 14, 1250—1254.
11. Shepherd, D., Donia, R.A., Cambell, J.A., Johnson, B.A., Holysz, R.P., Slomp, G., Stafford, J.E., Pederson, R.L., and Ott, A.C. (1955) *J. Am. Chem. Soc.*, 77, 1212—1216.
12. Ellingboe, J., Nystrom, E., and Sjoval, J. (1970) *J. Lipid Res.*, 11, 266—270.
13. Holick, M.F., and DeLuca, H.F. (1974) *Steroids Biochemistry and Pharmacology*, Vol. 4, M.H. Briggs and G.A. Christie (eds), pp. 111—155, Academic Press, New York.